Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06429722 · ClinicalTrials.gov registry record · Phase 2
To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder.
A Phase 2 study of Major Depressive Episode Associated With Bipolar II Disorder, sponsored by Neumora Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
- 20
- Study locations
NCT06429722 is a Phase 2 study of Major Depressive Episode Associated With Bipolar II Disorder that has completed, run by Neumora Therapeutics. The registered enrollment target is 18 participants. The trial reports 20 study locations across 10 states.
The verdict
NCT06429722, a Phase 2 study of Major Depressive Episode Associated With Bipolar II Disorder, has completed, sponsored by Neumora Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomized, double-blind, placebo-controlled pilot study aiming to evaluate the effects of NMRA-335140 on symptoms of major depression in adults with Bipolar (BP) II disorder. The study design consists of a Screening Period (up to 28 days), a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo), and a 6-week Safety Follow-up Period.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG NMRA-335140 80 mg
Study Locations (20)
Florida
- Neumora Investigator Site - Gainesville
- Neumora Investigator Site - Lauderhill
- Neumora Investigator Site - Maitland
- Neumora Investigator Site - Miami
- Neumora Investigator Site - Miami Lakes
California
- Neumora Investigator Site - Garden Grove
- Neumora Investigator Site - Long Beach
- Neumora Investigator Site - San Jose
- Neumora Investigator Site - Torrance
New Jersey
- Neumora Investigator Site - Marlton
- Neumora Investigator Site - Princeton
- Neumora Investigator Site - Toms River
Georgia
- Neumora Investigator Site - Marietta
- Neumora Investigator Site - Savannah
Arizona
- Neumora Investigator Site - Phoenix
Arkansas
- Neumora Investigator Site - Little Rock
Massachusetts
- Neumora Investigator Site - Watertown
Mississippi
- Neumora Investigator Site - Flowood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2024-05-13 |
| Est. Completion | 2025-05-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06429722
The ClinicalTrials.gov registry entry for NCT06429722 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neumora Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depressive Episode Associated With Bipolar II Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06429722 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, California, New Jersey.
Frequently Asked Questions
What is clinical trial NCT06429722 about?
NCT06429722 is a clinical study titled "To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder.". This is a randomized, double-blind, placebo-controlled pilot study aiming to evaluate the effects of NMRA-335140 on symptoms of major depression in adults with Bipolar (BP) II disorder. The study design consists of a Screening Period (up to 28 days), a 6-week Treatment Period (during which participa...
What is the current status of trial NCT06429722?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2024-05-13. Estimated completion is 2025-05-30.
What conditions does trial NCT06429722 study?
This clinical trial studies the following conditions: Major Depressive Episode Associated With Bipolar II Disorder.
What interventions are being tested in trial NCT06429722?
The interventions under investigation include: Placebo (DRUG), NMRA-335140 80 mg (DRUG).
Who is sponsoring clinical trial NCT06429722?
This trial is sponsored by Neumora Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06429722 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.